Clinical Trials Sponsored by Weprom

Total 93 results

Weprom

Recruiting

Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer (SARVADS 1)

Sarcopenia | Cancer of Head and Neck | CT Scan

France
Weprom

Recruiting

Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line (PHARAOM)

Diffuse Large B Cell Lymphoma

France
Weprom

Completed

Assessment of the Prevalence of Sarcopenia in Early Palliative Cancer Patients (SPACE)

Metastatic Cancer

France
Weprom

Recruiting

Feasibility of an Adapted Physical Activity Program for Patients Treated With an Autograft (APA²) (APA²)

Lymphoma | Myeloma | Autologous Transplant

France
Weprom

Completed

Retrospective Study on the Incidence and Management of Anemia in Oncology (RESPIRE)

Cancer | Anemia

France
Weprom

Not yet recruiting

Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy (SPACE2)

Leukemia, Myeloid, Acute | Metastatic Cancer | Cancer, Rectum | Myelodysplasia | Cancer, Breast | Myeloma | Leukemia, Lymphocytic, Acute | Cancer, Lung | Cancer Colon | Leukemia, Lymphocytic, Chronic | Cancer, Kidney | Cancer Pancreas | Cancer Prostate | Leukemia,Myeloid, Chronic | Cancer Ovaries

France
Weprom

Recruiting

Secondary Prognostic Index in RefrActory Lymphoma (SPiRAL)

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

France
Weprom
Kelindi

Completed

Optimization of Mother-child Dyad Follow-up by a Multidomain Application: Real-world Cross Sectional Study (MALO_2)

Post Partum Depression | Child Development Disorder

France
Weprom
Kelindi

Recruiting

Assessment of the Feasibility of Using a Smartphone Application for the Prevention and Screening of Burnout (BURNOUT ADVICE) (BURNOUT ADVICE)

Burnout, Professional

France
Weprom
Kelindi

Recruiting

A Smartphone Application for Screening of Developmental Disorders in Children

Development, Child

France
Weprom
Kelindi

Completed

Early Detection Neurodevelopmental Disorders of Children and Prevention of Postnatal Depression by Mobile Health App

Development, Child | Postnatal Depression

France
Weprom
Neptune

Active, not recruiting

Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) (OPTIMAG)

Metastatic Colorectal Cancer | Metastatic Head and Neck Cancer

France
Weprom
Kelindi

Completed

Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application (SourceCOVID)

Covid19

France
Weprom
Pfizer; FLGXPL

Recruiting

A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line (AxiPRO)

Renal Cell Carcinoma Metastatic

France
Weprom
L'effet Papillon

Completed

Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) (REVEH)

Hematologic Neoplasms

France
Weprom
Takeda; SIVAN Innovation

Terminated

Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response

Lymphoma, Large B-Cell, Diffuse | Lymphoma, T-Cell | Lymphoma, Hodgkin

France
Weprom
SIVAN Innovation Ldt

Completed

SENTINEL : Impact of the Use of a Web-application for the Detection of Lung Cancer Relapse (SENTINEL)

Lung Cancer

France
Weprom
Incyte Corporation; Resilience Care

Not yet recruiting

Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma (EMILY)

Diffuse Large B Cell Lymphoma

France
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Androxal

Bioequivalence

United States
Repros Therapeutics Inc.

Completed

Crossover Study of the Safety and PK Properties of Proellex®

Pharmacokinetics

United States
Repros Therapeutics Inc.

Terminated

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

Endometriosis

United States
Repros Therapeutics Inc.

Completed

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Terminated

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

ABSORPTION | METABOLISM | EXCRETION

United States
Repros Therapeutics Inc.

Withdrawn

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Uterine Fibroids

United States, Brazil
Repros Therapeutics Inc.

Completed

A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects

Healthy
Repros Therapeutics Inc.

Completed

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

Obesity | Acquired Hypogonadotropic Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

Pharmacokinetics

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Oral Administration

Healthy

United States
Repros Therapeutics Inc.

Completed

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Impaired Liver Function

United States
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States, Mexico
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal

Normal Volunteers
Repros Therapeutics Inc.

Completed

Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males

Drug-drug Interaction

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism (ZA-003Ext)

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Withdrawn

Open-Label Extension Study to ZPE-202

Endometriosis

United States
Repros Therapeutics Inc.

Completed

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

Hypogonadism | Low Testosterone

United States

3

Subscribe